{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,30]],"date-time":"2026-08-30T02:29:58Z","timestamp":1788056998676,"version":"build-2784847793"},"reference-count":41,"publisher":"Bioscientifica","issue":"4","license":[{"start":{"date-parts":[[2024,7,26]],"date-time":"2024-07-26T00:00:00Z","timestamp":1721952000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["etj.bioscientifica.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,7,26]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Thyroid eye disease (TED) is an autoimmune orbital disease, with intravenous glucocorticoid (IVGC) therapy as the first-line treatment. Due to uncertain response rates and possible side effects, various prediction models have been developed to predict IVGC therapy outcomes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A thorough search was conducted in PubMed, Embase, and Web of Science databases. Data extraction included publication details, prediction model content, and performance. Statistical analysis was performed using R software, including heterogeneity evaluation, publication bias, subgroup analysis, and sensitivity analysis. Forest plots were utilized for result visualization.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Of the 12 eligible studies, 47 prediction models were extracted. All included studies exhibited a low-to-moderate risk of bias. The pooled area under the receiver operating characteristic curve (AUC) and the combined sensitivity and specificity for the models were 0.81, 0.75, and 0.79, respectively. In view of heterogeneity, multiple meta-regression and subgroup analysis were conducted, which showed that marker and modeling types may be the possible causes of heterogeneity (\n                      <jats:italic>P<\/jats:italic>\n                      &lt; 0.001). Notably, imaging metrics alone (AUC\u2009=\u20090.81) or clinical characteristics combined with other markers (AUC\u2009=\u20090.87), incorporating with multivariate regression (AUC\u2009=\u20090.84) or radiomics analysis (AUC\u2009=\u20090.91), yielded robust and reliable prediction outcomes.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>This meta-analysis comprehensively reviews the predictive models for IVGC therapy response in TED. It underscores that integrating clinical characteristics with laboratory or imaging indicators and employing advanced techniques like multivariate regression or radiomics analysis significantly enhance the efficacy of prediction. Our research findings offer valuable insights that can guide future studies on prediction models for IVGC therapy in TED.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1530\/etj-24-0122","type":"journal-article","created":{"date-parts":[[2024,8,26]],"date-time":"2024-08-26T09:49:46Z","timestamp":1724665786000},"update-policy":"https:\/\/doi.org\/10.1530\/crossmarkpolicy-16","source":"Crossref","is-referenced-by-count":13,"title":["Prediction models of intravenous glucocorticoids therapy response in thyroid eye disease"],"prefix":"10.1530","volume":"13","author":[{"given":"Haiyang","family":"Zhang","sequence":"first","affiliation":[{"name":"Department of Ophthalmology, Shanghai Ninth People\u2019s Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China"},{"name":"Shanghai Key Laboratory of Orbital Diseases and Ocular Oncology, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuo","family":"Wu","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Shanghai Ninth People\u2019s Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China"},{"name":"Shanghai Key Laboratory of Orbital Diseases and Ocular Oncology, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuyu","family":"Hu","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Shanghai Ninth People\u2019s Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China"},{"name":"Shanghai Key Laboratory of Orbital Diseases and Ocular Oncology, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xianqun","family":"Fan","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Shanghai Ninth People\u2019s Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China"},{"name":"Shanghai Key Laboratory of Orbital Diseases and Ocular Oncology, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuefei","family":"Song","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Shanghai Ninth People\u2019s Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China"},{"name":"Shanghai Key Laboratory of Orbital Diseases and Ocular Oncology, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tienan","family":"Feng","sequence":"additional","affiliation":[{"name":"Clinical Research Institute, Shanghai Jiao Tong University School of Medicine, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8636-861X","authenticated-orcid":true,"given":"Huifang","family":"Zhou","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Shanghai Ninth People\u2019s Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China"},{"name":"Shanghai Key Laboratory of Orbital Diseases and Ocular Oncology, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"416","reference":[{"key":"bib1","series-title":"Zhonghua Yan Ke Za Zhi","first-page":"646","article-title":"Chinese guideline on the diagnosis and treatment of thyroid-associated ophthalmopathy (2022)","volume":"58","year":"2022","unstructured":"Oculoplastic and Orbital Disease Group of Chinese Ophthalmological Society of Chinese Medical Association & Thyroid Group of Chinese Society of Endocrinology of Chinese Medical Association. Chinese guideline on the diagnosis and treatment of thyroid-associated ophthalmopathy (2022). Zhonghua Yan Ke Za Zhi202258646\u2013668. (https:\/\/doi.org\/10.3760\/cma.j.cn112142-20220421-00201)"},{"key":"bib2","series-title":"European Journal of Endocrinology","first-page":"55","article-title":"The therapeutic outcome to intravenous steroid therapy for active Graves\u2019 orbitopathy is influenced by the time of response but not polymorphisms of the glucocorticoid receptor","volume":"170","author":"Vannucchi","year":"2014","unstructured":"Vannucchi GCovelli DCampi IOrigo DCurr\u00f2 NCirello VDazzi DBeck-Peccoz P & Salvi M. The therapeutic outcome to intravenous steroid therapy for active Graves\u2019 orbitopathy is influenced by the time of response but not polymorphisms of the glucocorticoid receptor. European Journal of Endocrinology201417055\u201361. (https:\/\/doi.org\/10.1530\/EJE-13-0611)"},{"key":"bib3","series-title":"European Journal of Endocrinology","first-page":"G43","article-title":"\u2019","volume":"185","author":"Bartalena","year":"2021","unstructured":"\u2019Bartalena LKahaly GJBaldeschi LDayan CMEckstein AMarcocci CMarin\u00f2 MVaidya BWiersinga WM & EUGOGO. The 2021 European Group on Graves\u2019 orbitopathy (EUGOGO) clinical practice guidelines for the medical management of Graves\u2019 orbitopathy. European Journal of Endocrinology2021185G43\u2013G67. (https:\/\/doi.org\/10.1530\/EJE-21-0479)"},{"key":"bib4","series-title":"British Journal of Ophthalmology","first-page":"639","article-title":"Clinical criteria for the assessment of disease activity in Graves\u2019 ophthalmopathy: a novel approach","volume":"73","author":"Mourits","year":"1989","unstructured":"Mourits MPKoornneef LWiersinga WMPrummel MFBerghout A & van der Gaag R. Clinical criteria for the assessment of disease activity in Graves\u2019 ophthalmopathy: a novel approach. British Journal of Ophthalmology198973639\u2013644. (https:\/\/doi.org\/10.1136\/bjo.73.8.639)"},{"key":"bib5","series-title":"Ophthalmic Plastic and Reconstructive Surgery","first-page":"157","article-title":"What is the aim of immunosuppressive treatment in patients with graves\u2019 orbitopathy?","volume":"30","author":"Yang","year":"2014","unstructured":"Yang MWiersinga WMSoeters MR & Mourits MP. What is the aim of immunosuppressive treatment in patients with graves\u2019 orbitopathy?Ophthalmic Plastic and Reconstructive Surgery201430157\u2013161. (https:\/\/doi.org\/10.1097\/IOP.0000000000000036)"},{"key":"bib6","series-title":"Journal of Magnetic Resonance Imaging","first-page":"862","article-title":"T2 -Weighted MR imaging-derived radiomics for pretreatment determination of therapeutic response to glucocorticoid in patients with thyroid-associated ophthalmopathy: comparison with semiquantitative evaluation","volume":"56","author":"Hu","year":"2022","unstructured":"Hu HChen LZhang JLChen WChen HHLiu HShi HBWu FY & Xu XQ. T2 -Weighted MR imaging-derived radiomics for pretreatment determination of therapeutic response to glucocorticoid in patients with thyroid-associated ophthalmopathy: comparison with semiquantitative evaluation. Journal of Magnetic Resonance Imaging202256862\u2013872. (https:\/\/doi.org\/10.1002\/jmri.28088)"},{"key":"bib7","series-title":"Clinical Endocrinology","first-page":"652","article-title":"Measuring TSH receptor antibody to influence treatment choices in Graves\u2019 disease","volume":"86","author":"Hesarghatta Shyamasunder","year":"2017","unstructured":"Hesarghatta Shyamasunder A & Abraham P. Measuring TSH receptor antibody to influence treatment choices in Graves\u2019 disease. Clinical Endocrinology201786652\u2013657. (https:\/\/doi.org\/10.1111\/cen.13327)"},{"key":"bib8","series-title":"Current Opinion in Ophthalmology","first-page":"385","article-title":"The pathophysiology of thyroid eye disease: implications for immunotherapy","volume":"22","author":"Douglas","year":"2011","unstructured":"Douglas RS & Gupta S. The pathophysiology of thyroid eye disease: implications for immunotherapy. Current Opinion in Ophthalmology201122385\u2013390. (https:\/\/doi.org\/10.1097\/ICU.0b013e3283499446)"},{"key":"bib9","series-title":"Thyroid","first-page":"403","article-title":"Acute and severe liver damage associated with intravenous glucocorticoid pulse therapy in patients with Graves\u2019 ophthalmopathy","volume":"14","author":"Marin\u00f3","year":"2004","unstructured":"Marin\u00f3 MMorabito EBrunetto MRBartalena LPinchera A & Marocci C. Acute and severe liver damage associated with intravenous glucocorticoid pulse therapy in patients with Graves\u2019 ophthalmopathy. Thyroid200414403\u2013406. (https:\/\/doi.org\/10.1089\/105072504774193276)"},{"key":"bib10","series-title":"British Journal of Ophthalmology","first-page":"773","article-title":"Impact of smoking on the response to treatment of thyroid associated ophthalmopathy","volume":"87","author":"Eckstein","year":"2003","unstructured":"Eckstein AQuadbeck BMueller GRettenmeier AWHoermann RMann KSteuhl P & Esser J. Impact of smoking on the response to treatment of thyroid associated ophthalmopathy. British Journal of Ophthalmology200387773\u2013776. (https:\/\/doi.org\/10.1136\/bjo.87.6.773)"},{"key":"bib11","series-title":"Korean Journal of Radiology","first-page":"664","article-title":"T2 mapping with and without fat-suppression to predict treatment response to intravenous glucocorticoid therapy for thyroid-associated ophthalmopathy","volume":"23","author":"Zhai","year":"2022","unstructured":"Zhai LWang QLiu PLuo BYuan G & Zhang J. T2 mapping with and without fat-suppression to predict treatment response to intravenous glucocorticoid therapy for thyroid-associated ophthalmopathy. Korean Journal of Radiology202223664\u2013673. (https:\/\/doi.org\/10.3348\/kjr.2021.0627)"},{"key":"bib12","series-title":"BMJ","first-page":"i6460","article-title":"A guide to systematic review and meta-analysis of prediction model performance","volume":"356","author":"Debray","year":"2017","unstructured":"Debray TPADamen JAAGSnell KIEEnsor JHooft LReitsma JBRiley RD & Moons KGM. A guide to systematic review and meta-analysis of prediction model performance. BMJ2017356i6460. (https:\/\/doi.org\/10.1136\/bmj.i6460)"},{"key":"bib13","series-title":"JAMA","first-page":"388","article-title":"Preferred reporting items for a systematic review and meta-analysis of diagnostic test accuracy studies: the PRISMA-DTA statement","volume":"319","author":"McInnes","year":"2018","unstructured":"McInnes MDFMoher DThombs BDMcGrath TABossuyt PM, and the PRISMA-DTA Group, Clifford TCohen JFDeeks JJGatsonis Cet al.Preferred reporting items for a systematic review and meta-analysis of diagnostic test accuracy studies: the PRISMA-DTA statement. JAMA2018319388\u2013396. (https:\/\/doi.org\/10.1001\/jama.2017.19163)"},{"key":"bib14","series-title":"Prospero","first-page":"CRD42023445393","article-title":"Prediction models of intravenous glucocorticoids therapy response in thyroid eye disease: A systematic review and meta-analysis","author":"Zhang","year":"2023","unstructured":"Zhang HWu SHu SSong X & Zhou H. Prediction models of intravenous glucocorticoids therapy response in thyroid eye disease: A systematic review and meta-analysis. Prospero2023CRD42023445393. Available at: https:\/\/www.crd.york.ac.uk\/prospero\/display_record.php?ID=CRD42023445393."},{"key":"bib15","series-title":"BMC Endocrine Disorders","first-page":"13","article-title":"A single-center retrospective study of factors related to the effects of intravenous glucocorticoid therapy in moderate-to-severe and active thyroid-associated ophthalmopathy","volume":"18","author":"Wang","year":"2018","unstructured":"Wang YZhang SZhang YLiu XGu HZhong SHuang YFang SSun JZhou Het al. A single-center retrospective study of factors related to the effects of intravenous glucocorticoid therapy in moderate-to-severe and active thyroid-associated ophthalmopathy. BMC Endocrine Disorders20181813. (https:\/\/doi.org\/10.1186\/s12902-018-0240-8)"},{"key":"bib16","series-title":"Clinical Endocrinology","first-page":"175","article-title":"Factors associated with the efficacy of intravenous methylprednisolone in moderate-to-severe and active thyroid-associated ophthalmopathy: A single-centre retrospective study","volume":"90","author":"Hu","year":"2019","unstructured":"Hu SWang YHe MZhang MDing X & Shi B. Factors associated with the efficacy of intravenous methylprednisolone in moderate-to-severe and active thyroid-associated ophthalmopathy: A single-centre retrospective study. Clinical Endocrinology201990175\u2013183. (https:\/\/doi.org\/10.1111\/cen.13855)"},{"key":"bib17","series-title":"Endocrine","first-page":"372","article-title":"Predicting the response to glucocorticoid therapy in thyroid-associated ophthalmopathy: mobilizing structural MRI-based quantitative measurements of orbital tissues","volume":"70","author":"Hu","year":"2020","unstructured":"Hu HXu XQChen LChen WWu QChen HHZhu HShi HB & Wu FY. Predicting the response to glucocorticoid therapy in thyroid-associated ophthalmopathy: mobilizing structural MRI-based quantitative measurements of orbital tissues. Endocrine202070372\u2013379. (https:\/\/doi.org\/10.1007\/s12020-020-02367-5)"},{"key":"bib18","series-title":"European Journal of Radiology","first-page":"109839","article-title":"Prediction of treatment response to intravenous glucocorticoid in patients with thyroid-associated ophthalmopathy using T2 mapping and T2 IDEAL","volume":"142","author":"Zhai","year":"2021","unstructured":"Zhai LLuo BWu HWang QYuan GLiu PMa YZhao Y & Zhang J. Prediction of treatment response to intravenous glucocorticoid in patients with thyroid-associated ophthalmopathy using T2 mapping and T2 IDEAL. European Journal of Radiology2021142109839. (https:\/\/doi.org\/10.1016\/j.ejrad.2021.109839)"},{"key":"bib19","series-title":"Endocrine Practice","first-page":"1268","article-title":"Role of magnetic resonance imaging in the assessment of active thyroid-associated ophthalmopathy patients with long disease duration","volume":"25","author":"Zhou","year":"2019","unstructured":"Zhou MShen LJiao QYe LZhou YZhu WWang W & Wang S. Role of magnetic resonance imaging in the assessment of active thyroid-associated ophthalmopathy patients with long disease duration. Endocrine Practice2019251268\u20131278. (https:\/\/doi.org\/10.4158\/EP-2019-0133)"},{"key":"bib20","series-title":"Thyroid","first-page":"299","article-title":"Role of magnetic resonance imaging in thyroid-associated ophthalmopathy: its predictive value for therapeutic outcome of immunosuppressive therapy","volume":"2","author":"Hiromatsu","year":"1992","unstructured":"Hiromatsu YKojima KIshisaka NTanaka KSato MNonaka KNishimura H & Nishida H. Role of magnetic resonance imaging in thyroid-associated ophthalmopathy: its predictive value for therapeutic outcome of immunosuppressive therapy. Thyroid19922299\u2013305. (https:\/\/doi.org\/10.1089\/thy.1992.2.299)"},{"key":"bib21","series-title":"Clinical Radiology","first-page":"159.e1","article-title":"T2 mapping histogram at extraocular muscles for predicting the response to glucocorticoid therapy in patients with thyroid-associated ophthalmopathy","volume":"76","author":"Hu","year":"2021","unstructured":"Hu HChen HHChen WWu QChen LZhu HXu XQShi HB & Wu FY. T2 mapping histogram at extraocular muscles for predicting the response to glucocorticoid therapy in patients with thyroid-associated ophthalmopathy. Clinical Radiology202176159.e1\u2013159.e8. (https:\/\/doi.org\/10.1016\/j.crad.2020.09.005)"},{"key":"bib22","series-title":"Endocrine Connections","first-page":"676","article-title":"Texture analysis of orbital magnetic resonance imaging for monitoring and predicting treatment response to glucocorticoids in patients with thyroid-associated ophthalmopathy","volume":"10","author":"Wang","year":"2021","unstructured":"Wang YYWu QChen LChen WYang TXu XQWu FYHu H & Chen HH. Texture analysis of orbital magnetic resonance imaging for monitoring and predicting treatment response to glucocorticoids in patients with thyroid-associated ophthalmopathy. Endocrine Connections202110676\u2013684. (https:\/\/doi.org\/10.1530\/EC-21-0162)"},{"key":"bib23","series-title":"Acta Ophthalmologica","first-page":"e154","article-title":"The application of temperature measurement of the eyes by digital infrared thermal imaging as a prognostic factor of methylprednisolone pulse therapy for Graves\u2019 ophthalmopathy","volume":"88","author":"Shih","year":"2010","unstructured":"Shih SRLi HYHsiao YL & Chang TC. The application of temperature measurement of the eyes by digital infrared thermal imaging as a prognostic factor of methylprednisolone pulse therapy for Graves\u2019 ophthalmopathy. Acta Ophthalmologica201088e154\u2013e159. (https:\/\/doi.org\/10.1111\/j.1755-3768.2010.01941.x)"},{"key":"bib24","series-title":"International Journal of Endocrinology","first-page":"3196059","article-title":"Thickness of extraocular muscle and orbital fat in MRI predicts response to glucocorticoid therapy in graves\u2019 ophthalmopathy","volume":"2017","author":"Xu","year":"2017","unstructured":"Xu LLi LXie CGuan M & Xue Y. Thickness of extraocular muscle and orbital fat in MRI predicts response to glucocorticoid therapy in graves\u2019 ophthalmopathy. International Journal of Endocrinology201720173196059. (https:\/\/doi.org\/10.1155\/2017\/3196059)"},{"key":"bib25","series-title":"Thyroid","first-page":"1439","article-title":"\u2019","volume":"32","author":"Burch","year":"2022","unstructured":"\u2019Burch HBPerros PBednarczuk TCooper DSDolman PJLeung AMMombaerts ISalvi M & Stan MN. Management of thyroid eye disease: a consensus statement by the American Thyroid Association and the European Thyroid Association. Thyroid2022321439\u20131470. (https:\/\/doi.org\/10.1089\/thy.2022.0251)"},{"key":"bib26","series-title":"American Journal of Ophthalmology","first-page":"94","article-title":"Inter-observer variability of clinical activity score: assessments in patients with thyroid eye disease","volume":"252","author":"Perros","year":"2023","unstructured":"Perros P\u017darkovi\u0107 MPearce SHRazvi SKolli H & Dickinson AJ. Inter-observer variability of clinical activity score: assessments in patients with thyroid eye disease. American Journal of Ophthalmology202325294\u2013100. (https:\/\/doi.org\/10.1016\/j.ajo.2023.03.027)"},{"key":"bib27","series-title":"American Journal of Neuroradiology","first-page":"1466","article-title":"Non-EPI-DWI for detection, disease monitoring, and clinical decision-making in thyroid eye disease","volume":"41","author":"Feeney","year":"2020","unstructured":"Feeney CLingam RKLee VRahman F & Nagendran S. Non-EPI-DWI for detection, disease monitoring, and clinical decision-making in thyroid eye disease. American Journal of Neuroradiology2020411466\u20131472. (https:\/\/doi.org\/10.3174\/ajnr.A6664)"},{"key":"bib28","series-title":"Eye","first-page":"1553","article-title":"Teprotumumab for the treatment of chronic thyroid eye disease","volume":"36","author":"Ugradar","year":"2022","unstructured":"Ugradar SKang JKossler ALZimmerman EBraun JHarrison ARBose SCockerham K & Douglas RS. Teprotumumab for the treatment of chronic thyroid eye disease. Eye2022361553\u20131559. (https:\/\/doi.org\/10.1038\/s41433-021-01593-z)"},{"key":"bib29","series-title":"Scientific Reports","first-page":"6259","article-title":"Imaging of the medial rectus muscle predicts the development of optic neuropathy in thyroid eye disease","volume":"12","author":"Berger","year":"2022","unstructured":"Berger MMatlach JPitz SBerres MAxmacher FKahaly GJBrockmann MA & M\u00fcller-Eschner M. Imaging of the medial rectus muscle predicts the development of optic neuropathy in thyroid eye disease. Scientific Reports2022126259. (https:\/\/doi.org\/10.1038\/s41598-022-10043-z)"},{"key":"bib30","series-title":"Therapeutic Advances in Ophthalmology","first-page":"25158414211027760","article-title":"Updates on the understanding and management of thyroid eye disease","volume":"13","author":"Men","year":"2021","unstructured":"Men CJKossler AL & Wester ST. Updates on the understanding and management of thyroid eye disease. Therapeutic Advances in Ophthalmology20211325158414211027760. (https:\/\/doi.org\/10.1177\/25158414211027760)"},{"key":"bib31","series-title":"Graefe\u2019s Archive for Clinical and Experimental Ophthalmology","first-page":"1195","article-title":"Autoantibody against aldehyde dehydrogenase 2 could be a biomarker to monitor progression of Graves\u2019 orbitopathy","volume":"256","author":"Cheng","year":"2018","unstructured":"Cheng KCWu YJCheng KHCheng KYChen KJWu WCLee PY & Chang CH. Autoantibody against aldehyde dehydrogenase 2 could be a biomarker to monitor progression of Graves\u2019 orbitopathy. Graefe\u2019s Archive for Clinical and Experimental Ophthalmology20182561195\u20131201. (https:\/\/doi.org\/10.1007\/s00417-017-3894-4)"},{"key":"bib32","series-title":"Hormone and Metabolic Research","first-page":"957","article-title":"Circulating CXCL9 and CXCL10 as markers of activity of Graves\u2019 orbitopathy during treatment with corticosteroids and teleradiotherapy","volume":"44","author":"Mysliwiec","year":"2012","unstructured":"Mysliwiec JPalyga IKosciuszko MKowalska A & Gorska M. Circulating CXCL9 and CXCL10 as markers of activity of Graves\u2019 orbitopathy during treatment with corticosteroids and teleradiotherapy. Hormone and Metabolic Research201244957\u2013961. (https:\/\/doi.org\/10.1055\/s-0032-1316352)"},{"key":"bib33","series-title":"Frontiers in Endocrinology","first-page":"991588","article-title":"Current insights of applying MRI in Graves\u2019 ophthalmopathy","volume":"13","author":"Song","year":"2022","unstructured":"Song CLuo YYu GChen H & Shen J. Current insights of applying MRI in Graves\u2019 ophthalmopathy. Frontiers in Endocrinology202213991588. (https:\/\/doi.org\/10.3389\/fendo.2022.991588)"},{"key":"bib34","series-title":"Journal of Magnetic Resonance Imaging","first-page":"1528","article-title":"Low-field MRI: an MR physics perspective","volume":"49","author":"Marques","year":"2019","unstructured":"Marques JPSimonis FFJ & Webb AG. Low-field MRI: an MR physics perspective. Journal of Magnetic Resonance Imaging2019491528\u20131542. (https:\/\/doi.org\/10.1002\/jmri.26637)"},{"key":"bib35","series-title":"European Radiology","first-page":"6251","article-title":"Radiomics analysis of dual-energy CT-derived iodine maps for diagnosing metastatic cervical lymph nodes in patients with papillary thyroid cancer","volume":"30","author":"Zhou","year":"2020","unstructured":"Zhou YSu GYHu HGe YQSi YShen MPXu XQ & Wu FY. Radiomics analysis of dual-energy CT-derived iodine maps for diagnosing metastatic cervical lymph nodes in patients with papillary thyroid cancer. European Radiology2020306251\u20136262. (https:\/\/doi.org\/10.1007\/s00330-020-06866-x)"},{"key":"bib36","series-title":"Scientific Reports","first-page":"2027","article-title":"Predictive factors of prognosis after radiation and steroid pulse therapy in thyroid eye disease","volume":"9","author":"Ito","year":"2019","unstructured":"Ito MTakahashi YKatsuda EOshima YTakeuchi AMori TAbe SMori YKakizaki H & Suzuki K. Predictive factors of prognosis after radiation and steroid pulse therapy in thyroid eye disease. Scientific Reports201992027. (https:\/\/doi.org\/10.1038\/s41598-019-38640-5)"},{"key":"bib37","series-title":"International Journal of Computer Assisted Radiology and Surgery","first-page":"323","article-title":"Artificial intelligence CT screening model for thyroid-associated ophthalmopathy and tests under clinical conditions","volume":"16","author":"Song","year":"2021","unstructured":"Song XLiu ZLi LGao ZFan XZhai G & Zhou H. Artificial intelligence CT screening model for thyroid-associated ophthalmopathy and tests under clinical conditions. International Journal of Computer Assisted Radiology and Surgery202116323\u2013330. (https:\/\/doi.org\/10.1007\/s11548-020-02281-1)"},{"key":"bib38","series-title":"Bioresource Technology","first-page":"128062","article-title":"Interpretable machine learning to model biomass and waste gasification","volume":"364","author":"Ascher","year":"2022","unstructured":"Ascher SWang XWatson ISloan W & You S. Interpretable machine learning to model biomass and waste gasification. Bioresource Technology2022364128062. (https:\/\/doi.org\/10.1016\/j.biortech.2022.128062)"},{"key":"bib39","series-title":"Frontiers in Endocrinology","first-page":"1079628","article-title":"Factors related to steroid treatment responsiveness in thyroid eye disease patients and application of SHAP for feature analysis with XGBoost","volume":"14","author":"Park","year":"2023","unstructured":"Park JKim JRyu D & Choi HY. Factors related to steroid treatment responsiveness in thyroid eye disease patients and application of SHAP for feature analysis with XGBoost. Frontiers in Endocrinology2023141079628. (https:\/\/doi.org\/10.3389\/fendo.2023.1079628)"},{"issue":"Supplement 1","key":"bib40","series-title":"European Thyroid Journal","first-page":"3","article-title":"Proposal for standardization of primary and secondary outcomes in patients with active, moderate-to-severe Graves\u2019 orbitopathy","volume":"9","author":"Bartalena","year":"2020","unstructured":"Bartalena L & Wiersinga WM. Proposal for standardization of primary and secondary outcomes in patients with active, moderate-to-severe Graves\u2019 orbitopathy. European Thyroid Journal20209(Supplement 1) 3\u201316. (https:\/\/doi.org\/10.1159\/000510700)"},{"key":"bib41","series-title":"Journal of Clinical Endocrinology and Metabolism","first-page":"145","article-title":"Public health relevance of Graves\u2019 orbitopathy","volume":"98","author":"Ponto","year":"2013","unstructured":"Ponto KAMerkesdal SHommel GPitz SPfeiffer N & Kahaly GJ. Public health relevance of Graves\u2019 orbitopathy. Journal of Clinical Endocrinology and Metabolism201398145\u2013152. (https:\/\/doi.org\/10.1210\/jc.2012-3119)"}],"container-title":["European Thyroid Journal"],"original-title":[],"link":[{"URL":"https:\/\/etj.bioscientifica.com\/view\/journals\/etj\/13\/4\/ETJ-24-0122.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/etj.bioscientifica.com\/downloadpdf\/journals\/etj\/13\/4\/ETJ-24-0122.xml","content-type":"text\/html","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/etj.bioscientifica.com\/downloadpdf\/journals\/etj\/13\/4\/ETJ-24-0122.xml","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T13:52:02Z","timestamp":1784555522000},"score":1,"resource":{"primary":{"URL":"http:\/\/journals.bioscientifica.com\/etj\/article\/4361"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,26]]},"references-count":41,"journal-issue":{"issue":"4"},"URL":"https:\/\/doi.org\/10.1530\/etj-24-0122","relation":{},"ISSN":["2235-0802"],"issn-type":[{"value":"2235-0802","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7,26]]}}}